The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein

被引：32

作者：

Chen, Xuemin ^{[1
,2
]}

Rostad, Christina A. ^{[1
,2
]}

Anderson, Larry J. ^{[1
,2
]}

Sun, He-ying ^{[1
]}

Lapp, Stacey A. ^{[1
,2
]}

Stephens, Kathy ^{[1
]}

Hussaini, Laila ^{[1
]}

Gibson, Theda ^{[1
]}

Rouphael, Nadine ^{[3
]}

Anderson, Evan J. ^{[1
,2
,3
]}

机构：

[1] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA

[2] Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines, Atlanta, GA USA

[3] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA

来源：

VIROLOGY | 2021年 / 559卷

基金：

美国国家卫生研究院;

关键词：

SARS-CoV-2; Antibody-dependent cell-mediated cytotoxicity (ADCC); COVID-19; Spike (S) protein; NK cells; Fc gamma RIIIa receptor (CD16); TARGET-CELLS; IN-VITRO; VACCINATION; REPORTER;

D O I：

10.1016/j.virol.2021.03.009

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Since the COVID-19 pandemic, functional non-neutralizing antibody responses to SARS-CoV-2, including antibody-dependent cell-mediated cytotoxicity (ADCC), are poorly understood. We developed an ADCC assay utilizing a stably transfected, dual-reporter target cell line with inducible expression of a SARS-CoV-2 spike protein on the cell surface. Using this assay, we analyzed 61 convalescent serum samples from adults with PCRconfirmed COVID-19 and 15 samples from healthy uninfected controls. We found that 56 of 61 convalescent serum samples induced ADCC killing of SARS-CoV-2 S target cells, whereas none of the 15 healthy controls had detectable ADCC. We then found a modest decline in ADCC titer over a median 3-month follow-up in 21 patients who had serial samples available for analysis. We confirmed that the antibody-dependent target cell lysis was mediated primarily via the NK Fc gamma RIIIa receptor (CD16). This ADCC assay had high sensitivity and specificity for detecting serologic immune responses to SARS-CoV-2.

引用

页码：1 / 9

页数：9

共 38 条

[1] Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study [J].

Abolghasemi, Hassan ;

Eshghi, Peyman ;

Cheraghali, Abdol Majid ;

Fooladi, Abbas Ali Imani ;

Moghaddam, Farzaneh Bolouki ;

Imanizadeh, Sina ;

Maleki, Matin Moeini ;

Ranjkesh, Mohammad ;

Rezapour, Mohammad ;

Bahramifar, Ali ;

Einollahi, Behzad ;

Hosseini, Mohammad Javad ;

Jafari, Nematollah Joneidi ;

Nikpouraghdam, Mohamad ;

Sadri, Nariman ;

Tazik, Mokhtar ;

Sali, Shanaz ;

Okati, Shamsi ;

Askari, Elham ;

Tabarsi, Payam ;

Aslani, Jafar ;

Sharifipour, Ehsan ;

Jarahzadeh, Mohammad Hossein ;

Khodakarim, Nastaran ;

Salesi, Mahmood ;

Jafari, Ramezan ;

Shahverdi, Samira .

TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (05)

[2] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].

Anderson, E. J. ;

Rouphael, N. G. ;

Widge, A. T. ;

Jackson, L. A. ;

Roberts, P. C. ;

Makhene, M. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. B. ;

Flach, B. ;

Lin, B. C. ;

Doria-Rose, N. A. ;

O'Dell, S. ;

Schmidt, S. D. ;

Corbett, K. S. ;

Swanson, P. A., II ;

Padilla, M. ;

Neuzil, K. M. ;

Bennett, H. ;

Leav, B. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Edara, V. V. ;

Floyd, K. ;

Suthar, M. S. ;

Martinez, D. R. ;

Baric, R. ;

Buchanan, W. ;

Luke, C. J. ;

Phadke, V. K. ;

Rostad, C. A. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438

[3]

[Anonymous], 2020, CELL, DOI DOI 10.1016/j.cell.2020.06.025

[4] Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody [J].

Asokan, Mangaiarkarasi ;

Dias, Joana ;

Liu, Cuiping ;

Maximova, Anna ;

Ernste, Keenan ;

Pegu, Amarendra ;

McKee, Krisha ;

Shi, Wei ;

Chen, Xuejun ;

Almasri, Cassandra ;

Promsote, Wanwisa ;

Ambrozak, David R. ;

Gama, Lucio ;

Hu, Jianfei ;

Douek, Daniel C. ;

Todd, John-Paul ;

Lifson, Jeffrey D. ;

Fourati, Slim ;

Sekaly, Rafick P. ;

Crowley, Andrew R. ;

Ackerman, Margaret E. ;

Ko, Sung Hee ;

Kilam, Divya ;

Boritz, Eli A. ;

Liao, Laura E. ;

Best, Katharine ;

Perelson, Alan S. ;

Mascola, John R. ;

Koup, Richard A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (31) :18754-18763

[5] Distinct Early Serological Signatures Track with SARS-CoV-2 Survival [J].

Atyeo, Caroline ;

Fischinger, Stephanie ;

Zohar, Tomer ;

Slein, Matthew D. ;

Burke, John ;

Loos, Carolin ;

McCulloch, Denise J. ;

Newman, Kira L. ;

Wolf, Caitlin ;

Yu, Jingyou ;

Shuey, Kiel ;

Feldman, Jared ;

Hauser, Blake Marie ;

Caradonna, Tim ;

Schmidt, Aaron G. ;

Suscovich, Todd J. ;

Linde, Caitlyn ;

Cai, Yongfei ;

Barouch, Dan ;

Ryan, Edward T. ;

Charles, Richelle C. ;

Lauffenburger, Douglas ;

Chu, Helen ;

Alter, Galit .

IMMUNITY, 2020, 53 (03) :524-+

[6] Convalescent plasma to treat COVID-19 [J].

Bloch, Evan M. .

BLOOD, 2020, 136 (06) :654-655

[7]

BRUNNER KT, 1968, IMMUNOLOGY, V14, P181

[8] Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay [J].

Chen, Xuemin ;

Anderson, Larry J. ;

Rostad, Christina A. ;

Ding, Lingmei ;

Lai, Lilin ;

Mulligan, Mark ;

Rouphael, Nadine ;

Natrajan, Muktha S. ;

McCracken, Courtney ;

Anderson, Evan J. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2021, 488

[9] Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection [J].

de Vries, Rory D. ;

Nieuwkoop, Nella J. ;

Pronk, Mark ;

de Bruin, Erwin ;

Leroux-Roels, Geert ;

Huijskens, Elisabeth G. W. ;

van Binnendijk, Rob S. ;

Krammer, Florian ;

Koopmans, Marion P. G. ;

Rimmelzwaan, Guus F. .

VACCINE, 2017, 35 (02) :238-247

[10]

Dogan Mikail, 2020, medRxiv, DOI 10.1101/2020.07.07.20148106

← 1 2 3 4 →